Subscribe
montego-shutterstock-com
montego / Shutterstock.com
3 July 2015Americas

Biosimilars market value could triple by 2020, says report

The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
The plausibility battleground at the EPO
9 November 2020   Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
Americas
US FDA approves first biosimilar, keeps quiet on naming standards
9 March 2015   The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.
Biotechnology
Association calls for more biosimilar cancer therapies in Europe
11 October 2018   Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Europe
The plausibility battleground at the EPO
9 November 2020   Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
Americas
US FDA approves first biosimilar, keeps quiet on naming standards
9 March 2015   The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.
Biotechnology
Association calls for more biosimilar cancer therapies in Europe
11 October 2018   Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.

More on this story

Europe
The plausibility battleground at the EPO
9 November 2020   Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
Americas
US FDA approves first biosimilar, keeps quiet on naming standards
9 March 2015   The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.
Biotechnology
Association calls for more biosimilar cancer therapies in Europe
11 October 2018   Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York